E, M., M, F., AC, W., F, D. L., ML, V., H, S., . . . V, H. (2026). Immunogenicity and Safety of the AS01E-adjuvanted Respiratory Syncytial Virus (RSV) Prefusion F Protein Vaccine in Adults Aged 18-49 Years at Increased Risk of RSV Disease Compared with Adults Aged ≥60 Years. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 82(5), e1093. https://doi.org/10.1093/cid/ciag058
Chicago Style (17th ed.) CitationE, Mitha, et al. "Immunogenicity and Safety of the AS01E-adjuvanted Respiratory Syncytial Virus (RSV) Prefusion F Protein Vaccine in Adults Aged 18-49 Years at Increased Risk of RSV Disease Compared with Adults Aged ≥60 Years." Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America 82, no. 5 (2026): e1093. https://doi.org/10.1093/cid/ciag058.
MLA (9th ed.) CitationE, Mitha, et al. "Immunogenicity and Safety of the AS01E-adjuvanted Respiratory Syncytial Virus (RSV) Prefusion F Protein Vaccine in Adults Aged 18-49 Years at Increased Risk of RSV Disease Compared with Adults Aged ≥60 Years." Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America, vol. 82, no. 5, 2026, p. e1093, https://doi.org/10.1093/cid/ciag058.
